In line with the assumption that NTRK-fusion-driven cancers are largely devoid of other oncogenic drivers, NTRK gene fusions were less likely to co-occur with common drivers, such as those involved in MAPK and PI3K signalling pathways (KRAS, PIK3CA) and with known oncogenic driver genes in breast cancer, CRC and NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.